Aeroflex Industries Limited: Complete Company Overview

Origins and Milestones

Aeroflex Industries Limited emerged in the mid‑1990s as part of India’s growing pharmaceutical landscape. Founded by a group of seasoned chemists, the company initially focused on bulk drug production before expanding into finished dosage forms. Over the past three decades it has transitioned from a modest manufacturing unit to a publicly listed entity on the Bombay Stock Exchange.

Core Product Portfolio

The firm’s catalogue spans a broad spectrum of therapeutic areas, including cardiovascular, anti‑infective, and anti‑inflammatory medicines. Its flagship products are generic versions of well‑known international drugs, marketed under both domestic and export labels. In addition to tablets and capsules, Aeroflex manufactures injectables and ophthalmic solutions, catering to both hospital and retail channels.

Manufacturing Footprint and Quality Systems

Aeroflex operates several GMP‑certified plants strategically located in Gujarat and Maharashtra. Each site boasts modern formulation lines, high‑potency synthesis units, and dedicated quality control labs. The company’s commitment to compliance is underscored by regular audits from the US FDA and the European Medicines Agency, allowing it to export to more than 30 countries.

Financial Highlights

Recent financial statements indicate a steady revenue trajectory, with growth driven primarily by export orders and an expanding domestic generic market. Profit margins have benefited from cost‑optimization initiatives, such as lean manufacturing and strategic sourcing of raw materials. While exact figures fluctuate yearly, analysts generally describe Aeroflex’s financial health as “stable with upside potential.”

Market Presence and Distribution Network

Domestically, the company leverages a network of over 2,000 distributors, reaching pharmacies across major Indian states. Internationally, it relies on partnerships with global contract manufacturers and wholesalers, ensuring presence in key markets like the United States, Europe, and the Middle East. This dual‑pronged approach helps balance revenue streams and mitigate regional regulatory risks.

Recent Developments and Strategic Outlook

In the last few years Aeroflex has pursued diversification through acquisitions of smaller niche players, adding specialty formulations to its lineup. It also announced plans to invest in a new R&D center focused on biosimilars, reflecting the industry’s shift toward biologics. Looking ahead, the company aims to increase its export share to exceed 40 % of total sales, while continuing to strengthen domestic market penetration through value‑added services.

Corporate Governance and Sustainability

The board of Aeroflex includes seasoned professionals from pharma, finance, and regulatory backgrounds, ensuring balanced decision‑making. Sustainability initiatives cover waste reduction, energy‑efficient operations, and community health programs in the regions surrounding its plants. Stakeholders increasingly view these efforts as integral to the company’s long‑term credibility.

Challenges and Risk Factors

Like many Indian pharma firms, Aeroflex faces pricing pressure from government drug price caps and intense competition from both local and multinational generic manufacturers. Supply‑chain volatility, especially for active pharmaceutical ingredients sourced abroad, poses another layer of uncertainty. The company’s ability to navigate regulatory changes in major export markets will also be a decisive factor in its growth trajectory.

Key Takeaways

• Broad product range spanning tablets, injectables, and ophthalmics.
• Robust manufacturing with multiple GMP‑certified facilities and international quality approvals.
• Balanced market strategy that combines extensive domestic distribution with a growing export footprint.
• Future focus on biosimilars and strategic acquisitions to diversify the portfolio.

Frequently Asked Questions

What types of medicines does Aeroflex specialize in?

Aeroflex produces generic formulations across several therapeutic classes, notably cardiovascular, anti‑infective, anti‑inflammatory, and ophthalmic drugs.

Is Aeroflex Industries Limited listed on a stock exchange?

Yes, the company is publicly traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

Does Aeroflex export its products?

The firm exports to more than 30 countries, leveraging FDA and EMA certifications to access regulated markets in the US, Europe, and the Middle East.

What are the company’s future growth areas?

Recent announcements highlight a focus on biosimilars, increased R&D spending, and strategic acquisitions to broaden its specialty drug offerings.